How to modulate FXR activity to treat the Metabolic Syndrome

Drug Discovery Today: Disease Mechanisms

Volumn 6, Issue 1-4, 2009, Pages

  Prawitt, Janne ^a,b,c   Caron, Sandrine ^a,b,c   Staels, Bart ^a,b,c  

^a UNIV LILLE   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; BILE ACID; BILE ACID SEQUESTRANT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FARNESOID X RECEPTOR; FIBRIC ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; GUGGULSTERONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; LIPID; MEGLITINIDE; NICOTINIC ACID; RECEPTOR BLOCKING AGENT; SELECTIVE BILE ACID RECEPTOR MODULATOR; SIBUTRAMINE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADIPOSE TISSUE; ATHEROSCLEROSIS; BILE ACID METABOLISM; BILE ACID SYNTHESIS; BLOOD VESSEL TONE; BLOOD VESSEL WALL; CARDIOVASCULAR FUNCTION; DRUG POTENCY; DRUG TARGETING; ENTEROHEPATIC CIRCULATION; GENE EXPRESSION REGULATION; GENETIC REGULATION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; INTESTINE; KIDNEY; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIVER; METABOLIC SYNDROME X; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROCESSING; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77956647363     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2010.05.002     Document Type: Review

References (98)

1. S.M. Grundy Metabolic syndrome pandemic Arterioscler. Thromb. Vasc. Biol. 28 2008 629 636
2. J.T. Haas Dissecting the role of insulin resistance in the metabolic syndrome Curr. Opin. Lipidol. 20 2009 206 210
3. M. Cornier The metabolic syndrome Endocr. Rev. 29 2008 777 822
4. E. Fabbrini Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity Proc. Natl. Acad. Sci. U. S. A. 106 2009 15430 15435
5. A. Kotronen Liver fat in the metabolic syndrome J. Clin. Endocrinol. Metab. 92 2007 3490 3497
6. A. Kotronen Fatty liver: a novel component of the metabolic syndrome Arterioscler. Thromb. Vasc. Biol. 28 2008 27 38
7. S.B. Biddinger Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis Cell Metab. 7 2008 125 134
8. H. Gronemeyer Principles for modulation of the nuclear receptor superfamily Nat. Rev. Drug Discov. 3 2004 950 964
9. P. Lefebvre Role of bile acids and bile acid receptors in metabolic regulation Physiol. Rev. 89 2009 147 191
10. R. Gineste Phosphorylation of farnesoid x receptor by protein kinase c promotes its transcriptional activity Mol. Endocrinol. 22 2008 2433 2447
11. J.K. Kemper Fxr acetylation is normally dynamically regulated by p300 and sirt1 but constitutively elevated in metabolic disease states Cell Metab. 10 2009 392 404
12. M. Makishima Identification of a nuclear receptor for bile acids Science 284 1999 1362 1365
13. D.J. Parks Bile acids: natural ligands for an orphan nuclear receptor Science 284 1999 1365 1368
14. H. Wang Endogenous bile acids are ligands for the nuclear receptor fxr/bar Mol. Cell 3 1999 543 553
15. S. Fiorucci Bile-acid-activated receptors: targeting tgr5 and farnesoid-x-receptor in lipid and glucose disorders Trends Pharmacol. Sci. 30 2009 570 580
16. M.C. Bateson Chenodeoxycholic acid therapy for hypertriglyceridaemia in men Br. J. Clin. Pharmacol. 5 1978 249 254
17. S. Bilz Activation of the farnesoid x receptor improves lipid metabolism in combined hyperlipidemic hamsters Am. J. Physiol. Endocrinol. Metab. 290 2006 E716 E722
18. M. Watanabe Bile acids lower triglyceride levels via a pathway involving fxr, shp, and srebp-1c J. Clin. Invest. 113 2004 1408 1418
19. T. Claudel Farnesoid x receptor agonists suppress hepatic apolipoprotein CIII expression Gastroenterology 125 2003 544 555
20. H.R. Kast Farnesoid x-activated receptor induces apolipoprotein c-ii transcription: a molecular mechanism linking plasma triglyceride levels to bile acids Mol. Endocrinol. 15 2001 1720 1728
21. M. Nakahara Bile acids enhance low density lipoprotein receptor gene expression via a mapk cascade-mediated stabilization of mrna J. Biol. Chem. 277 2002 37229 37234
22. C. Langhi Activation of the farnesoid x receptor represses pcsk9 expression in human hepatocytes FEBS Lett. 582 2008 949 955
23. L.J. Schoenfield Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the national cooperative gallstone study. A controlled trial of efficacy and safety Ann. Intern. Med. 95 1981 257 282
24. Y. Wang Effects of chenodeoxycholic acid and deoxycholic acid on cholesterol absorption and metabolism in humans Transl. Res. 148 2006 37 45
25. G. Lambert The farnesoid x-receptor is an essential regulator of cholesterol homeostasis J. Biol. Chem. 278 2003 2563 2570
26. Y. Zhang Identification of novel pathways that control farnesoid x receptor-mediated hypocholesterolemia J. Biol. Chem. 285 2010 3035 3043
27. O. Leiss Different effects of chenodeoxycholic acid and ursodeoxycholic acid on serum lipoprotein concentrations in patients with radiolucent gallstones Scand. J. Gastroenterol. 17 1982 587 592
28. B. Kong Farnesoid x receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet J. Pharmacol. Exp. Ther. 328 2009 116 122
29. S. Zhang Farnesoid x receptor agonist way-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis J. Hepatol. 51 2009 380 388
30. S. Zhang Suppression of interleukin-6-induced c-reactive protein expression by fxr agonists Biochem. Biophys. Res. Commun. 379 2009 476 479
31. Y. Wang Farnesoid x receptor antagonizes nuclear factor kappab in hepatic inflammatory response Hepatology 48 2008 1632 1643
32. S. Fiorucci The nuclear receptor shp mediates inhibition of hepatic stellate cells by fxr and protects against liver fibrosis Gastroenterology 127 2004 1497 1512
33. P. Fickert Farnesoid x receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts Am. J. Pathol. 175 2009 2392 2405
34. B. Staels Bile acid sequestrants and the treatment of type 2 diabetes mellitus Drugs 67 2007 1383 1392
35. D. Duran-Sandoval Glucose regulates the expression of the farnesoid x receptor in liver Diabetes 53 2004 890 898
36. D. Duran-Sandoval The farnesoid x receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition J. Biol. Chem. 280 2005 29971 29979
37. 13C nuclear magnetic resonance study J. Clin. Invest. 90 1992 1323 1327
38. Y. Zhang Activation of the nuclear receptor fxr improves hyperglycemia and hyperlipidemia in diabetic mice Proc. Natl. Acad. Sci. U. S. A. 103 2006 1006 1011
39. K.R. Stayrook Regulation of carbohydrate metabolism by the farnesoid x receptor Endocrinology 146 2005 984 991
40. K. Ma Farnesoid x receptor is essential for normal glucose homeostasis J. Clin. Invest. 116 2006 1102 1109
41. E. De Fabiani Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle J. Biol. Chem. 278 2003 39124 39132
42. K. Yamagata Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and foxo1 J. Biol. Chem. 279 2004 23158 23165
43. B. Cariou The farnesoid x receptor modulates adiposity and peripheral insulin sensitivity in mice J. Biol. Chem. 281 2006 11039 11049
44. S. Cipriani Fxr activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in zucker (fa/fa) obese rats J. Lipid Res. 51 2009 771 784
45. G. Medina-Gomez Ppar gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism PLoS Genet. 3 2007 e64
46. S.L. Gray Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor gamma function (p465l ppargamma) in mice Diabetes 55 2006 2669 2677
47. A.J. Lusis Atherosclerosis Nature 407 2000 233 241
48. D. Bishop-Bailey Expression and activation of the farnesoid x receptor in the vasculature Proc. Natl. Acad. Sci. U. S. A. 101 2004 3668 3673
49. F. He Downregulation of endothelin-1 by farnesoid x receptor in vascular endothelial cells Circ. Res. 98 2006 192 199
50. J. Li Fxr-mediated regulation of enos expression in vascular endothelial cells Cardiovasc. Res. 77 2008 169 177
51. T. Hu Farnesoid x receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase- 1 gene regulation J. Biol. Chem. 281 2006 39831 39838
52. J. Li Coordinated regulation of dimethylarginine dimethylaminohydrolase-1 and cationic amino acid transporter-1 by farnesoid x receptor in mouse liver and kidney and its implication in the control of blood levels of asymmetric dimethylarginine J. Pharmacol. Exp. Ther. 331 2009 234 243
53. T. Kida Chronic stimulation of farnesoid x receptor impairs nitric oxide sensitivity of vascular smooth muscle Am. J. Physiol. Heart Circ. Physiol. 296 2009 H195 201
54. G.L. Guo Effects of fxr in foam-cell formation and atherosclerosis development Biochim. Biophys. Acta 1761 2006 1401 1409
55. E.A. Hanniman Loss of functional farnesoid x receptor increases atherosclerotic lesions in apolipoprotein e-deficient mice J. Lipid Res. 46 2005 2595 2604
56. Y. Zhang Fxr deficiency causes reduced atherosclerosis in ldlr-/- mice Arterioscler. Thromb. Vasc. Biol. 26 2006 2316 2321
57. B. Flatt Discovery of xl335 (way-362450), a highly potent, selective, and orally active agonist of the farnesoid x receptor (fxr) J. Med. Chem. 52 2009 904 907
58. H.B. Hartman Activation of farnesoid x receptor prevents atherosclerotic lesion formation in ldlr-/- and apoe-/- mice J. Lipid Res. 50 2009 1090 1100
59. A. Mencarelli Antiatherosclerotic effect of farnesoid x receptor Am. J. Physiol. Heart Circ. Physiol. 296 2009 H272 H281
60. H. Herrema Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid x receptor- and liver x receptoralpha-controlled metabolic pathways in mice Hepatology 51 2010 806 816
61. A. Garg Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial Ann. Intern. Med. 121 1994 416 422
62. B. Staels Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration Diabetes Care 32 Suppl 2 2009 S237 S245
63. C. Beysen Colesevelam hcl improves glucose metabolism and increases plasma glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide concentrations in subjects with type 2 diabetes Diabetologia 52 Suppl1 2009 S77
64. P.R. Maloney Identification of a chemical tool for the orphan nuclear receptor fxr J. Med. Chem. 43 2000 2971 2974
65. N.E. Miller Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia Lancet 2 1974 929 931
66. S. Mudaliar Farnesoid-x receptor agonists - a new therapeutic class for diabetes and nafld - first clinical data Diabetologia 52 Suppl 1 2009 S78
67. I. Dussault Identification of an endogenous ligand that activates pregnane x receptor-mediated sterol clearance Proc. Natl. Acad. Sci. U. S. A. 100 2003 833 838
68. B. Pourcet Selective ppar modulators, dual and pan ppar agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis Expert Opin. Emerg. Drugs 11 2006 379 401
69. D.P. McDonnell Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators Recent Prog. Horm. Res. 57 2002 295 316
70. B. Goodwin A regulatory cascade of the nuclear receptors fxr, shp-1, and lrh-1 represses bile acid biosynthesis Mol. Cell 6 2000 517 526
71. K.E. Matsukuma Coordinated control of bile acids and lipogenesis through fxr-dependent regulation of fatty acid synthase J. Lipid Res. 47 2006 2754 2761
72. I. Pineda Torra Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid x receptor Mol. Endocrinol. 17 2003 259 272
73. T. Claudel Bile acid-activated nuclear receptor fxr suppresses apolipoprotein a-i transcription via a negative fxr response element J. Clin. Invest. 109 2002 961 971
74. X. Prieur The human apolipoprotein av gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid x-activated receptor response element J. Biol. Chem. 278 2003 25468 25480
75. H. Hirokane Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4 J. Biol. Chem. 279 2004 45685 45692
76. A.M. Anisfeld Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-x receptor J. Biol. Chem. 278 2003 20420 20428
77. A. Sirvent The farnesoid x receptor induces very low density lipoprotein receptor gene expression FEBS Lett. 566 2004 173 177
78. N.L. Urizar The farnesoid x-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression J. Biol. Chem. 275 2000 39313 39317
79. M.L. Hubbert Regulation of hepatic insig-2 by the farnesoid x receptor Mol. Endocrinol. 21 2007 1359 1369
80. R.S. Savkur Regulation of pyruvate dehydrogenase kinase expression by the farnesoid x receptor Biochem. Biophys. Res. Commun. 329 2005 391 396
81. A.M. Anisfeld Activation of the nuclear receptor fxr induces fibrinogen expression: a new role for bile acid signaling J. Lipid Res. 46 2005 458 468
82. A. Zhao Human kininogen gene is transactivated by the farnesoid x receptor J. Biol. Chem. 278 2003 28765 28770
83. J. Li Regulation of complement c3 expression by the bile acid receptor fxr J. Biol. Chem. 280 2005 7427 7434
84. P. Qin Bile acid signaling through fxr induces intracellular adhesion molecule-1 expression in mouse liver and human hepatocytes Am. J. Physiol. Gastrointest. Liver Physiol. 289 2005 G267 G273
85. A. Gutierrez Bile acids decrease hepatic paraoxonase 1 expression and plasma high-density lipoprotein levels via fxr-mediated signaling of fgfr4 Arterioscler. Thromb. Vasc. Biol. 26 2006 301 306
86. Q. Zhang Fxr-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells Cardiovasc. Res. 77 2008 560 569
87. Y.T.Y. Li Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration Arterioscler. Thromb. Vasc. Biol. 27 2007 2606 2611
88. J.A. Holt Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis Genes Dev. 17 2003 1581 1591
89. S. Bhatnagar Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis J. Biol. Chem. 284 2009 10023 10033
90. H. Shen Farnesoid x receptor induces glut4 expression through fxr response element in the glut4 promoter Cell. Physiol. Biochem. 22 2008 1 14
91. M.J. Evans A synthetic farnesoid x receptor (fxr) agonist promotes cholesterol lowering in models of dyslipidemia Am. J. Physiol. Gastrointest. Liver Physiol. 296 2009 G543 G552
92. C. Thomas Targeting bile-acid signalling for metabolic diseases Nat. Rev. Drug Discov. 7 2008 678 693
93. J. Cui Guggulsterone is a farnesoid x receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump J. Biol. Chem. 278 2003 10214 10220
94. P.O. Szapary Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial JAMA 290 2003 765 772
95. U. Beil Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides Metab. Clin. Exp. 31 1982 438 444
96. J. Shepherd The effects of cholestyramine on high density lipoprotein metabolism Atherosclerosis 33 1979 433 444
97. M. Itoh Comparison of efficacy of pitavastatin and colestimide in Japanese patients with diabetes mellitus complicated by hyperlipidaemia and metabolic syndrome Diabetologia 52 Suppl 1 2009 S491
98. K.G.M.M. Alberti Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity Circulation 120 2009 1640 1645